Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Hydrocodone | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Magnesium sulfate | The therapeutic efficacy of Edivoxetine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Edivoxetine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Mirtazapine | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Orphenadrine | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Pramipexole | Edivoxetine may increase the sedative activities of Pramipexole. |
| Ropinirole | Edivoxetine may increase the sedative activities of Ropinirole. |
| Rotigotine | Edivoxetine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Edivoxetine. |
| Sodium oxybate | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Thalidomide | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Edivoxetine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Edivoxetine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Edivoxetine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Edivoxetine is combined with (S)-Warfarin. |
| Ethanol | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Edivoxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Alaproclate. |
| Iobenguane | Edivoxetine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zopiclone | The risk or severity of adverse effects can be increased when Edivoxetine is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Edivoxetine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Edivoxetine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Edivoxetine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Edivoxetine. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Edivoxetine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Edivoxetine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Edivoxetine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Edivoxetine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Edivoxetine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Edivoxetine. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Edivoxetine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Edivoxetine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Edivoxetine. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Edivoxetine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Edivoxetine. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Edivoxetine. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Edivoxetine. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Edivoxetine. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Edivoxetine. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Edivoxetine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Edivoxetine. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Edivoxetine. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Edivoxetine. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Edivoxetine. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Edivoxetine. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Edivoxetine. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Edivoxetine. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Edivoxetine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Edivoxetine. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Edivoxetine. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Edivoxetine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Edivoxetine. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Edivoxetine. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Edivoxetine. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Edivoxetine. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Edivoxetine. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Edivoxetine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Edivoxetine. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Edivoxetine. |